Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)

By sjmartinez • January 9, 2025

Spring LM, Scarpetti L, Medford AJ, Niemierko A, Comander A, Mulvey T, Schnipper L, Isakoff SJ, Moy B, Wander SA, Shin J, Ephrem Z, Laposta AR, Denault E, Abraham E, Calistro G, Kalashnikova E, Rodriguez A, Liu MC, Aleshin A, Peppercorn J, Ellisen LW, Bardia A. Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER). NPJ Breast Cancer. 2025 Jan 7;11(1):2. doi: 10.1038/s41523-024-00708-5. PMID: 39774684.

Tags: Hematology/Oncology, Publications

Iron Deficiency Anemia in Children During and After PICU Stay: Single-Center Retrospective Cohort, 2021-2022

Vadivelan A, Nemeth E, Ganz T, Bulut Y. Iron Deficiency Anemia in Children During and After PICU Stay: Single-Center Retrospective Cohort, 2021-2022. Pediatr Crit Care[...]

Plasma Protein Biomarkers for the Cognitive Functions in Women Living with HIV

Li W, Rubin LH, Xu YH, Wang G, Li D, Vance DE. Plasma Protein Biomarkers for the Cognitive Functions in Women Living with HIV. Alzheimers[...]

RE: Enhancing Capacity for Primary Care Research in Cancer Survivorship: National Cancer Institute Meeting Report

McClellan SP, Rivera-Avila DA, Cardenas E, Pérez-Zepeda MU, Dykens JA, Weine SM, Fitzgibbon M, Ganz P, García-Peña C. RE: Enhancing Capacity for Primary Care Research[...]